{
    "clinical_study": {
        "@rank": "56888", 
        "acronym": "ABSOLUTE", 
        "arm_group": [
            {
                "arm_group_label": "Tamsulosin + Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Tamsulosin 0.2mg + Placebo 5 mg daily until clinical progression"
            }, 
            {
                "arm_group_label": "Tamsulosin + Finasteride", 
                "arm_group_type": "Active Comparator", 
                "description": "Tamsulosin 0.2mg + Finasteride 5 mg daily until clinical progression"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the clinical efficacy of alpha-blocker monotherapy\n      and alpha-blocker + 5-alpha reductase inhibitor combination therapy in benign prostate\n      hyperplasia patients, and suggest guidelines of the combination therapy."
        }, 
        "brief_title": "Advanced Benefits of Alpha-blocker Monotherapy on Lower Urinary Tracts Symptoms(LUTS) Patients", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Benign Prostate Hyperplasia", 
        "condition_browse": {
            "mesh_term": [
                "Prostatic Hyperplasia", 
                "Hyperplasia"
            ]
        }, 
        "detailed_description": {
            "textblock": "Even though it should be decided on patients cautiously under careful consideration about\n      prostate volume, Prostate Specific Antigen(PSA) level, symptom score and maximum uroflow,\n      recently the combination therapy of alpha-blocker and 5-alpha reductase inhibitor has been\n      tried imprudently in Korea.\n\n      As a result of several clinical trials which had conducted overseas for releasing the\n      combination drug of alpha-blocker and 5-alpha reductase inhibitor, the superiority of the\n      combination therapy has been proved, however, plenty of patients still don't derive\n      additional profit from it.\n\n      Therefore, in this study, the investigators anticipate to meet with meaningful results on\n      the clinical efficacy of alpha-blocker monotherapy and alpha-blocker + 5-alpha reductase\n      inhibitor combination therapy in Korean benign prostate hyperplasia patients, and provide\n      guidelines of the combination therapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male patients aged over 50\n\n          -  Clinically diagnosed benign prostate hyperplasia(BPH)\n\n          -  8 \u2264 IPSS \u2264 30\n\n          -  4 ml/sec \u2264 Q max \u2264 15 ml/sec\n\n          -  minimum voided volume \u2265 125 ml\n\n          -  Post voided residual volume \u2264 250\n\n          -  Volunteer who singed on informed consent documents\n\n        Exclusion Criteria:\n\n          -  Past history of surgical procedure experience related to BPH\n\n          -  Past history of taking 5-alpha reductase inhibitor(5-ARI) within 6 months before\n             screening, or for more than 12 months regardless of the point of time\n\n          -  Past history of taking alpha blocker within 2 weeks before screening\n\n          -  Past history of acute urinary retention within 3 months before screening\n\n          -  Serum PSA \u2265 10 ng/ml (but, in the case of  4 ng/ml \u2264 PSA < 10 ng/ml, the patients can\n             be included only if prostate cancer is excluded by prostate biopsy)\n\n          -  Anatomical abnormalities of lower urinary tracts(urethrostenosis, diverticulosis,\n             bladder neck contracture)\n\n          -  Clinical status that affects voiding other than BPH(neurogenic bladder, Chronic\n             Prostatitis/Chronic Pelvic Pain Syndrome, urinary infection, etc.)\n\n          -  Unstable and significant medical condition including below\n\n               -  Unstable angina pectoris, myocardial infarction, cerebrovascular disease within\n                  6 months before screening\n\n               -  Past history of malignant tumor including skin basal cell carcinoma within 5\n                  years before screening\n\n               -  Medically uncontrollable diabetes mellitus, peptic ulcer disease\n\n               -  Severe hepatic diseases\n\n               -  Past history of renal failure or renal disease (serum creatinine > 1.4mg/dl)\n\n               -  Condition expected serious adverse event due to the investigational drug\n\n          -  Other conditions considered not eligible for the trial upon investigator's judgement"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "545", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01736033", 
            "org_study_id": "TMS1011"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Tamsulosin + Placebo", 
                    "Tamsulosin + Finasteride"
                ], 
                "description": "1 tablet(0.2mg) orally q.d.", 
                "intervention_name": "Tamsulosin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Harnal D (brand name in Asia)", 
                    "Flomax"
                ]
            }, 
            {
                "arm_group_label": "Tamsulosin + Finasteride", 
                "description": "1 tablet(5mg) orally q.d.", 
                "intervention_name": "Finasteride", 
                "intervention_type": "Drug", 
                "other_name": "Proscar"
            }, 
            {
                "arm_group_label": "Tamsulosin + Placebo", 
                "description": "1 tablet(0.2mg) orally q.d.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Adrenergic alpha-Antagonists", 
                "Tamsulosin", 
                "Finasteride", 
                "5-alpha Reductase Inhibitors"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Lower Urinary Tracts Symptoms", 
            "5 alpha reductase inhibitor", 
            "Proscar", 
            "Finasteride", 
            "alpha blocker", 
            "Tamsulosin", 
            "Harnal D"
        ], 
        "lastchanged_date": "May 13, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Cheongju", 
                        "country": "Korea, Republic of", 
                        "state": "Chungbuk"
                    }, 
                    "name": "Chungbuk National University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cheonan", 
                        "country": "Korea, Republic of", 
                        "state": "Chungnam"
                    }, 
                    "name": "Soon Chun Hyang University Hospital Cheonan"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Anyang", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeoggi"
                    }, 
                    "name": "Hallym University Sacred Heart Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bucheon", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeonggi"
                    }, 
                    "name": "Soon Chun Hyang University Hospital Bucheon"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bucheon", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeonggi"
                    }, 
                    "name": "Bucheon St. Mary's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seongnam", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeonggi"
                    }, 
                    "name": "Seoul National University Bundang Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suwon", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeonggi"
                    }, 
                    "name": "Ajou University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hwasun", 
                        "country": "Korea, Republic of", 
                        "state": "Jeonnam"
                    }, 
                    "name": "Chonnam National University Hwasun Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Busan", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Pusan National University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Eulji General Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "110-744"
                    }, 
                    "name": "Seoul National University Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Randomized, Double-blind, Clinical Study to Investigate the Efficacy and Safety of Treatment With Tamsulosin 0.2mg Mono and Tamsulosin 0.2mg, Finasteride 5mg Combination Therapy in Patients With LUTS/BPH", 
        "overall_official": {
            "affiliation": "Seoul National University Hospital", 
            "last_name": "Soo Woong Kim, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "One of below\nDeterioration of the symptoms\nAcute urinary retention\nRenal failure\nRecurrent urinary tract infection\nUrinary incontinence\nSurgical procedure related to benign prostate hyperplasia", 
            "measure": "Clinical Progression", 
            "safety_issue": "No", 
            "time_frame": "1 & 2 months after baseline, and then every 3 months up to 4 years"
        }, 
        "reference": [
            {
                "PMID": "7539174", 
                "citation": "Shapiro E, Lepor H. Pathophysiology of clinical benign prostatic hyperplasia. Urol Clin North Am. 1995 May;22(2):285-90."
            }, 
            {
                "PMID": "1714529", 
                "citation": "Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet. 1991 Aug 24;338(8765):469-71."
            }, 
            {
                "PMID": "7532234", 
                "citation": "Bosch JL, Kranse R, van Mastrigt R, Schr\u00f6der FH. Reasons for the weak correlation between prostate volume and urethral resistance parameters in patients with prostatism. J Urol. 1995 Mar;153(3 Pt 1):689-93."
            }, 
            {
                "citation": "The prevalence of benign prostatic hyperplasia in elderly men in Korea: a community-based study. Park HK, Park H, Cho S, Bae J, Jeong S, Hong SK, et al. Korean J Urol 2009;50:843-7."
            }, 
            {
                "PMID": "2462301", 
                "citation": "Lepor H, Gup DI, Baumann M, Shapiro E. Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia. Urology. 1988 Dec;32(6 Suppl):21-6."
            }, 
            {
                "PMID": "9117115", 
                "citation": "Noble AJ, Chess-Williams R, Couldwell C, Furukawa K, Uchyiuma T, Korstanje C, Chapple CR. The effects of tamsulosin, a high affinity antagonist at functional alpha 1A- and alpha 1D-adrenoceptor subtypes. Br J Pharmacol. 1997 Jan;120(2):231-8."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01736033"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Seoul National University Hospital", 
            "investigator_full_name": "Soo Woong Kim, MD", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "International Prostate Symptom Score(IPSS)", 
                "safety_issue": "No", 
                "time_frame": "1 & 2 months after baseline, and then every 3 months up to 4 years"
            }, 
            {
                "measure": "International Consultation on Incontinence Modular Questionnaire(ICIQ) male LUTS-short form", 
                "safety_issue": "No", 
                "time_frame": "every 6 months up to 4 years"
            }, 
            {
                "description": "including Qmax, voided volume and post-void residual volume(PVR)", 
                "measure": "Uroflowmetry", 
                "safety_issue": "No", 
                "time_frame": "every 6 months up to 4 years"
            }, 
            {
                "measure": "Prostate volume", 
                "safety_issue": "No", 
                "time_frame": "every 1 year up to 4 years"
            }, 
            {
                "measure": "Global Response Assessment(GRA)", 
                "safety_issue": "No", 
                "time_frame": "every 1 year up to 4 years"
            }, 
            {
                "description": "PSA level will be examined in the central laboratory and be reported to each center as an adjusted number. It is because PSA level tends to decrease to 50% of baseline after taking finasteride for 1~4 years, so there is possibilities that the blindedness is broken with the actual result.", 
                "measure": "PSA level", 
                "safety_issue": "Yes", 
                "time_frame": "every 1 year up to 4 years"
            }, 
            {
                "description": "including Sodium, Potassium, Glucose, Urea nitrogen, Creatinine, ASpartate Transaminase(AST), ALanine Transaminase(ALT), Total bilirubin", 
                "measure": "Blood Chemistry", 
                "safety_issue": "Yes", 
                "time_frame": "every 1 year up to 4 years"
            }, 
            {
                "measure": "Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "every visit up to 4 years"
            }, 
            {
                "description": "Digital Rectal Exam, Breast exam", 
                "measure": "Physical examination", 
                "safety_issue": "Yes", 
                "time_frame": "every 1 year up to 4 years"
            }, 
            {
                "measure": "Male Sexual Health Questionnaire", 
                "safety_issue": "Yes", 
                "time_frame": "every 6 months up to 4 years"
            }
        ], 
        "source": "Seoul National University Hospital", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Astellas Pharma Korea, Inc.", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Medical Research Collaborating Center, Seoul, Korea", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Seoul National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}